VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the closing of its previously announced underwritten public offering of 25,645,000 common shares, including 3,345,000 common shares pursuant to the full exercise of the underwriters’ option...Read the Full Article
Monday, March 13, 2017 Louis Laflamme, President & Chief Executive Officer, Opsens Inc. (OPS), joined Ungad Chadda, President, Capital Formation, Equity Capital Markets, TMX Group to open the market. Opsens focuses mainly on the measure of Fractional Flow Reserve (FFR) in interventional cardiology. Opsens offers an optical-based pressure guidewire (OptoWire) that aims...Read the Full Article
TORONTO, March 9, 2017 /PRNewswire/ - Exact Imaging (www.exactimaging.com), the world's leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announced it has received Health Canada approval and the corresponding medical device license (#98667) to sell its ExactVu™ high resolution micro-ultrasound system. "We are very pleased...Read the Full Article
Learn More-External LinkRead the Full Article
QUEBEC CITY, Feb. 28, 2017 /CNW Telbec/ - Opsens Inc. ("Opsens" or the "Company") (TSXV: OPS) (OTCQX: OPSSF) is pleased to announce that it has received final approval for the listing of the Corporation's common shares (the "Common Shares") on the Toronto Stock Exchange ("TSX"). The Common Shares will commence trading on...Read the Full Article
SAN CARLOS, Calif., Jan. 25, 2017 /PRNewswire/ -- BAROnova, Inc., announced completion of its randomized cohort enrollment in the ENDObesity II Study, a multicenter randomized pivotal clinical trial designed to test the safety and effectiveness of the TransPyloric Shuttle® (TPS®), which treats obesity. Richard Rothstein, MD, the lead investigator of the study...Read the Full Article
Learn More-External LinkRead the Full Article
Atlanta, GA. – Celtaxsys, a clinical stage pharmaceutical development company focused on advancing novel anti-inflammatory treatment for rare and orphan diseases, announced today the appointment of Dr. Abel De La Rosa to the company board of directors. He currently serves as Chief Scientific Officer for the Drug Innovations Venture at Emory (DRIVE)...Read the Full Article
January 05, 2017 05:00 AM Eastern Standard Time VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced the successful achievement of a research milestone in a second immune-modulating bispecific antibody in...Read the Full Article
TORONTO, Jan. 5, 2017 /PRNewswire/ - Exact Imaging (www.exactimaging.com), the world's leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announced it has secured CDN $21.5 million in a Series C investment to commercialize its ExactVu™ micro-ultrasound system. The financing, which closed late in 2016, was...Read the Full Article